ReviewPortuguese journal of public health2025
Unveiling the Cost-Effectiveness of Chlamydia Screening Strategies: A Systematic Review.
Review in Portuguese journal of public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An agent-based platform for simulating the impact of chlamydia vaccine in the US population.Nature communications · 2026Article
- Divergent Burden Profiles of HIV/AIDS and Other Sexually Transmitted Infections Among Women of Child-Bearing Age, 1990-2021.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cost-effectiveness analyses of preventive screening strategies are paramount for public health to ensure effective resource use, especially for sexually transmitted infections such as Chlamydia, which lead to significant quality-adjusted life years (QALY) loss. Summary: This study systematically reviewed EMBASE, PubMed, and SCOPUS databases, from inception to October 2022, Chlamydia infection screening strategies' cost-effectiveness studies analyzing Incremental Cost Effectiveness Ratio (ICER) of QALYs versus no screening. Out of 487 studies, six were included, each employing distinct screening approaches, assumptions, and prevalence and incidence rates. The ICERs varied from USD 2,350/QALY gained with annual screening of women aged 15-24 years to EUR 117,529/QALY gained with women and men screening (age 16-29). Key Messages: The results underscore the impact of the different assumptions on ICERs and highlight the importance of precise epidemiology on Chlamydia infections. Studies characterizing the local population are crucial for accurate cost-effectiveness analysis and public health policy formulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.